News

Earlier, in January 2010, Vion has filed a SPA with the FDA related to a randomised Phase II/III trial of Onrigin in combination with low-dose Ara-C (LDAC) in

With this cooperation, Kemwell and Boehringer Ingelheim will provide customers with technology from Europe along with the benefit of low cost manufacturing from India. Process technology will originate

Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest. Elan said that

In May 2009 DSM and MCC already announced the signing of a memorandum of understanding for the intended swap. For both companies the businesses they will add to

Synta is currently enrolling patients in a Phase 2 single-arm, open-label, single-agent study of STA-9090 in patients with stage IIIB or IV non-small cell lung cancer, with patient

Patients in both arms received standard of care treatment for severe sepsis in an intensive care unit (ICU) setting. As previously reported, the trial achieved its primary endpoint

The ‘GreenVax Project’ will demonstrate evidence of concept for a large-scale facility producing vaccine using Nicotiana plants grown hydroponically in a contained environment. iBio claimed that its green

AFFiRiS said that the specific reason for the ‘outing’ of project no 4 was the approval of public research promotion funds by the FFG. The vaccine is targeting

Both agencies have consented to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the US and the